토토 사이트 바카라 Group acquires ANYGEN, strengthening peptide technology portfolio

[by Ji, Yong Jun] 토토 사이트 바카라 Group has acquired ANYGEN, gaining access to manufacturing technology that has recently been in the spotlight for GLP-1 obesity treatments.

ANYGEN announced on March 10 that seven affiliates of 토토 사이트 바카라 Group will participate in a third-party allocation paid-in capital increase amounting to KRW 15 billion (approximately USD 10.2 million) and will acquire KRW 5 billion in convertible bonds (CB). Separately, financial investors (FIs) will acquire KRW 5 billion in paid-in capital and KRW 35 billion in CB. In total, 토토 사이트 바카라 Group and other investors are committing KRW 60 billion toward the acquisition of ANYGEN.

With the funds secured, ANYGEN plans to expedite the development of an obesity treatment that offers significantly improved efficacy and pharmacokinetics (PK) compared to existing GLP-1 obesity treatments. The company also aims to formalize its collaboration with 토토 사이트 바카라 Pharma, which is developing a long-acting injection obesity treatment.

토토 사이트 바카라 operates the only peptide manufacturing facility in Korea under GMP (Good Manufacturing Practice) standards. The raw pharmaceutical products 'Leuprorelin' and 'Ganirelix' are currently awaiting cGMP (current Good Manufacturing Practice) review by the U.S. Food and Drug Administration (FDA).

Leuprorelin and Ganirelix are raw pharmaceutical 토토 사이트 바카라 products that regulate the function of G-protein-coupled receptors (GPCRs). Leuprorelin is used to treat conditions such as precocious puberty, prostate cancer, and endometriosis that occur in early puberty, while Ganirelix is ​​an infertility treatment that suppresses premature ovulation.

토토 사이트 바카라 Group has been consolidating the 'HBS (토토 사이트 바카라 Bio eco-System)', a collaborative framework designed to foster organic cooperation among its biotechnology affiliates. The group intends to leverage ANYGEN's peptide technology to develop advanced anticancer drugs, including 'peptide-drug conjugates (PDCs)'.

“With the addition of 토토 사이트 바카라 Group’s financial resources and technological expertise, we aim to achieve stable sales growth by strengthening the CDMO business and accelerating clinical progress in various areas like obesity and diabetes treatments, anticancer drugs, and antibiotics,” said Im Chang-yoon, Vice Chairman of the 토토 사이트 바카라 Group M&A.